Logo
Login

Company Executives

$ Management Team

Mr. Mark Iwicki

Independent Chairman of the Board

Age 57
Compensation $174.6K USD
Sex Male

Ms. Natalie Holles

Chief Executive Officer

Director

Age 51
Compensation $2.542M USD
Sex Female

Mr. Christopher Murphy

Chief Financial and Business Officer and Principal financial officer

Age 40
Compensation -
Sex Male

Ms. Julie Person

Chief Administrative Officer

Age 50
Compensation $1.114M USD
Sex Female

Dr. Edward Conner

Chief Medical Officer

Age 51
Compensation $1.384M USD
Sex Male

Board of Directors

From the proxy statement filed Apr 25, 2025
Directors
7
serving now
Independent
0 of 1
stated in the proxy; 6 not stated
Average tenure
4.2 years
from year joined
CEO also chairs the board
No
Mark Iwicki
Director Age On board Independent Committees Other public boards 2024 pay Source
Thomas M. Soloway
58 2022
3 years
 Not stated
Audit Committee · Chair Nominating and Governance Committee
None stated $259,144
David Bonita, M.D.
49 2020
5 years
 Not stated
Compensation Committee
Acutus Medical, Inc., Ikena Oncology, Inc., Prelude Therapeutics, Inc., Repare Therapeutics Inc. $245,144
Geoff McDonough, M.D.
54 2024
1 year
 Not stated
Audit Committee Nominating and Governance Committee
None stated $451,977
Mark Iwicki
Board chair
 58 Not stated Not stated
Compensation Committee · Chair
Merus N.V. $280,144
Natalie Holles
CEO
 52 2021
4 years
 Not independent None stated None stated Paid as CEO
Michael Gladstone
38 2019
6 years
 Not stated
Compensation Committee
Day One Biopharmaceuticals, Inc., Diagonal Therapeutics, Inc., Pheon Therapeutics Inc., Aiolos Bio, Inc. $245,144
H. Martin Seidel, Ph.D.
60 2019
6 years
 Not stated
Audit Committee Nominating and Governance Committee · Chair
None stated $253,906

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

No related-party transactions disclosed

The proxy filed Apr 25, 2025 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans